29TH ANNUAL CONFERENCE
ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER
PROGRAM BOOK
Ever since its inception, in August 1978 in Singapore, APASL (Asian Pacific Association for the Study of the Liver) never looks back but stick to its goal towards advancing the science and practice of Hepatology. Today it is one of the leading associations based on investigation and treatment of liver diseases in the world and the largest scientific body that upholds the standards and profession, research and creates improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region. APASL’s main objectives are to promote the latest scientific advancement and education of hepatology science, exchange of information and the development of consensus, encourage the practice of medicine in liver diseases and also coordinate scientific studies between various scientists and clinicians throughout the region.

We hold scientific educational symposia/conferences developed by leading hepatologists periodically. Our events feature expert speakers presenting the finest data in the most happening topics of liver diseases with high-quality scientific-technical presentations, followed by varied supporting program. Each of our events intended to meet the growing demands of hepatology as a core medical specialty and offers participants the right platform to exchange research, discuss outcomes, and interact with colleagues, focused on liver diseases. Our members are elected on their documented scientific publications. Mentorship, sharing of knowledge and dedication to professional growth and development are among the core values of APASL and its members.

It is a great pleasure for us to invite you to the 29th Annual Conference Asian Pacific for The Study of Liver (APASL) 2020 that will be held 4 - 8th March 2020 in Bali Nusa Dua Convention Center (BNDCC), Bali, Indonesia. The Conference program covering all aspects of hepatology, for that purpose this would be the perfect moment for all of us to join and share the experience, knowledge and also giving the benefits for the population in the Asian Pacific Region.

We are looking forward to welcoming you to Bali.

Sincerely,

Laurentius A. Lesmana
Honorary President

Rino Alvani Gani
President

Irsan Hasan
Vice President
APASL 2020 at Bali is the first major Liver meeting of 2020 in the world. It will bring cutting edge science, evidence based new therapies and guidelines. Join the academic feast and the enjoy beautiful and hospitable Bali.

Shiv K Sarin

ORGANIZING COMMITTEE

International Advisors
Dong Jin Suh
George K Lau
J H Kao
Ji-Dong Jia
Jin L Hou
Masao Omata
Osamu Yokosuka
Shiv K Sarin
Teerha Piratvisuth
Jose Sollano

National Advisors
Ali Sulaiman
Gontar A. Siregar
IDN Wibawa
Iswan A. Nusi
Julius
Lukman Hakim Zain
Nurul Akbar
Siti Aminah A.
Unggul Budihusodo
Laurentius A. Lesmana

Honorary President
Laurentius A Lesmana

President
Rino Alvani Gani

Vice President
Irsan Hasan

Secretary General
Andri Sanityoso Sulaiman

Treasurer
Juferdy Kurniawan

Scientific Committee

Chairman
C. Rinaldi Lesmana

Saut Horas Nababan
Chyntia O. M. Jasirwan
Lianda Siregar
Sahat Matondang
Toar JM Lalisang
Hanifah Oswari
Ening Krisnuhoni
Jacub Pandelaki
Errawan Wiradisuria
Imelda M. Loho

Organizing Committee

Bradley J. Waleleng
Bogi Pratomo W.
Kemal Fariz Kalista
Poernomo Boedi
Hery D jagat P.
David H. Muljono
Fardah Akil
Gontar A. Siregar
Begawan Bestari
Arles
Putut Bayupurnama
Ali Imron Yusuf

Conference Information

Date: 4 - 8th March 2020 | Website: www.apasl2020.org | Location: BALI NUSA DUA CONVENTION CENTER (BNDCC) BALI
Kawasan Terpadu ITDC NW/1 Nusa Dua - Bali 80363, Indonesia | Contact Person: (Gerry) +62 838 2045 4145
Conference Information

Venue
BALI NUSA DUA CONVENTION CENTER
Kawasan Terpadu ITDC NW/1 Nusa Dua - Bali 80363 Indonesia
T. +62-361-773000; F. +62-361-778880

Host
Asian Pacific Association for the Study of the Liver (APASL)

Organizer
PT. Prohepa

Conference Secretariat
Office 2 Ground Floor BNDCC 1

Official Language
English

Official Website
www.apasl2020.org

Registration

Registration Counter Opening Hours:
4 March 2020, Wednesday 08.00 - 18.30
5 March 2020, Thursday 07.00 - 16.00
6 March 2020, Friday 08.00 - 17.00
7 March 2020, Saturday 08.00 - 17.00

Poster Area

A Scientific poster session will be held during the APASL 2020 to highlight recent development. Please proceed your poster arrangement according to the schedule.

Poster Area will be located at Kintamani Lobby (Mezzanine Floor) and Singaraja Lobby (First Floor)
Conference Information

Wifi
SSID : APASL 2020
Password : APASLbali

Exhibition
There will be an exhibition in conjunction with the Symposium. The exhibition will exhibit the latest technology of pharmacy, diagnostic and therapeutic product in Hepatopancreatobiliary Diseases. The exhibition is located at South Lobby, East Lobby, Jimbaran Lobby 1 & 2 Bali Nusa Dua Convention Center 1

Exhibition Date and Time:
Instalation March, 3th & 4th, 2020
5 March 2020, Thursday 08.00 - 17.00
6 March 2020, Friday 08.00 - 17.00
7 March 2020, Saturday 08.00 - 17.00

Speaker Ready Room
Located at Uluwatu 6 BNDCC 1

Exhibition Date and Time:
Instalation March, 3th & 4th, 2020
5 March 2020, Thursday 08.00 - 17.00
6 March 2020, Friday 08.00 - 17.00
7 March 2020, Saturday 08.00 - 17.00

Abstract
Oral Presentation will be located at Mengwi Room 2, 3 & 5
Poster Area will be located at Kintamani Lobby (Mezzanine Floor) and Singaraja Lobby (First Floor)

Hotel Accomodation
Our Partnership Hotel :
Bali Nusa Dua Beach
Marriot Courtyard
Grand Hyatt Bali
The Westin Resort Nusa Dua Bali
Conrad Bali
Hilton Bali
The Laguna Resort and Spa
Internet Station

BALI NUSA DUA CONVENTION CENTER
Kawasan Terpadu ITDC NW/1 Nusa Dua - Bali 80363 Indonesia
T. +62-361-773000; F. +62-361-778880

Certificate of Attendance

The Committee will send all the certificate to each of emails that already registrated in the website system.

Mobile Phone

Please be aware that mobile phones must be switched off during all scientific sessions.

Photography

Taking pictures using flash is forbidden during all scientific sessions.

Lost & Found

Located at Business Centre BNDCC 1

Climate

Indonesia is distinctly tropical. The weather in Bali in September is usually hot and humid with temperatures ranging between 28 – 32 degrees Celsius and the relative humidity is about 88%. There is comparatively little difference between the day time and night time temperatures. All conference sessions will be held in air-conditioned venues.

Electric Current

The electric current in use throughout Indonesia is 220 volt at 50 cycles. In hotels, you may found two sockets for 110 and 220 volt each; or a converter may be obtained through the housekeeping. Power Plug 220 V.
Taxi

Taxis are available at the airport arrival area. Fare around IDR 250,000 or approximately USD 19. Make sure you take a cab from the official stand and NOT from someone offering taxi inside the terminal.

Customs

Maximum items allowed by customs when you visit Indonesia:
- 1 liter of alcoholic beverages
- 200 cigarettes OR 50 cigars OR 100 grams of tobacco
- Perfume the customs probably will not mind you carrying loads of bottles.
- Cameras, video cameras, portable radios, cassette recorders, binoculars and sport equipment are should be taken out during airport departure process. They must be declared to Customs.

You are prohibited to carry:
- Firearms
- Narcotics drugs
- Pornography materials
- Chinese printing and medicines
- Transceivers and cordless telephone
- Films, pre-recorded video tapes, laser discs, VCDs, DVDs must be screened by Censor Board.

Further information on customs and taxes in Indonesia, log into www.beacukai.go.id

IDD

<table>
<thead>
<tr>
<th>EMERGENCY NUMBER</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Police</td>
<td>110 / +62 - 361 - 110</td>
</tr>
<tr>
<td>Fire Department</td>
<td>113 / +62 - 361 - 113</td>
</tr>
<tr>
<td>Ambulance</td>
<td>118 / +62 - 361 - 118</td>
</tr>
<tr>
<td>Sanglah Public Hospital</td>
<td>+62 - 361 - 227 - 911</td>
</tr>
<tr>
<td>Search &amp; Rescue</td>
<td>111, 115 / 151 +62 - 361 - 751 11</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DIRECTORY TELEPHONE NUMBER INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bali</td>
</tr>
<tr>
<td>Indonesia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OPERATOR ASSISTED CALLS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within Indonesia</td>
</tr>
<tr>
<td>International</td>
</tr>
</tbody>
</table>

COUNTRY CODE: +62
CITY CODE: 361
Thursday 05.03.2020

Mengwi Room - Session I

13.00-15.00 Chairman: Edward Gane, Australia
Co-Chair: Abimanyu, Indonesia

13.00-13.10 Preoperative Risk Assessment for Delirium After Hepatic Resection in the Elderly: A Prospective Multicenter Study
Atsushi Ishihara

13.10-13.20 Relative dose intensity is very important to maximize the effect of lenvatinib among advance hepatocellular carcinoma patients
Takamasa Ohki

13.20-13.30 Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, double-blind, randomized, placebo-controlled, phase II trial
Takaomi Kessoku

13.30-13.40 Impact of laparoscopic liver resection for hepatocellular carcinoma on the development of postoperative complication
Daisuke Shirai

13.40-13.50 Real World Drug Resistance Profile of Hepatitis C Patients Who Failed Direct-Acting Antivirals
Federico Garcia

13.50-14.00 Genotype Misclassification and Its Impact on Treatment Choices, Outcomes and Drug Resistance
Federico Garcia

14.00-14.10 Characteristic of Resistance-Associated Substitutions in Unusual Hepatitis C Virus (HCV) Subtypes
Federico Garcia

Thursday 05.03.2020

Mengwi Room - Session I

13.00-15.00 Chairman: Aghayeva Gulnara, Azerbaijan
Co-Chair: Fuad Bakry, Indonesia

13.00-13.10 Post-treatments of lenvatinib in patients with advanced hepatocellular carcinoma
Susumu Maruta

13.10-13.20 Can near point of care HCV RNA tests serve as holy grail in the HCV care continuum: an evaluation study of Genedrive HCV RNA test
Padhi Abhishek

13.20-13.30 Outcomes of non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) at New Zealand Liver transplant Unit (NZLTU) over last 2 decades
Edward Gane

13.30-13.40 Dose response with RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB)
Edward Gane

13.40-13.50 First clinical experience with RNA interference [RNAi]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA)
Edward Gane

13.50-14.00 Clinical profile, etiology, outcome and predictors of outcome in upper gastrointestinal bleed patients presenting to medical emergency in a tertiary care centre in India
Anurag Sachan

14.00-14.10 Atezolizumab-bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC): Results from the Global and China enrollment phases of IMbrave150
Sairy Hernandez

14.10-14.20 Roles of alcohol consumption in fatty liver in Japanese men and women: A longitudinal study
Moriya Akio
Hepatoprotective effect of Tylophora villosa Blume Leaves Extract on Aspartate Aminotransferase and Alanine Aminotransferase Blood Concentrations of Sprague-Dawley Rat Models Induced by Rifampicin and Isoniazid

Sylvia Rianissa Putri

Pancreatic endosonographic changes in portal cavenorma cholangiopathy and effect of portosystemic shunt surgery in children

Moinak Sen Sarma

Co-relation of ascitic fluid (AF) appearance, symptoms & severity of cirrhosis in predicting Spontaneous bacterial peritonitis (SBP) in patients of chronic liver disease

Kandpal Ajay

Comparative study on treatment outcome of Sitagliptin on histological activity and fibrosis score between diabetic and non-diabetic patients with biopsy proven nonalcoholic steatohepatitis

Jhumur Ghosh

Five Year Experience with 2-Octyl Cyanoacrylate Injection in Gastric Varices in Cardinal Santos Medical Center

Ellaine Wei-Munji

Tenofovir Alafenamide for chronic hepatitis B patients with Advanced Fibrosis and Partial Virologic Responses to oral nucleos(t)ide analogues “An Interim Report”

Ming-Lung Yu

Factor associated with treatment failure of DAA for chronic hepatitis C - a nationwide real-world HCV Registry Program (TACR) in Taiwan

Ming-Lung Yu

Modelling Quality-Adjusted Life Years (QALYs) for Patients with Non-alcoholic Fatty Liver Disease (NAFLD) in Hong Kong

Vincent Wong

Elevated testosterone increases the risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus

Terry Cheuk-Fung Yip
Mengwi 2 Room - Session I
Young Investigator Awards

10.00-12.00  
Chairman : CH Liu, Taiwan  
Co-Chair : Rushwandi, Indonesia

10.00-10.10  
Long term outcomes with carvedilol versus propanolol in patients with index variceal bleed: 6-year follow-up of a randomised controlled trial
Srikant Mohta

10.10-10.20  
The Incidence of Acute Kidney Injury after platinum-based transcatheter arterial chemembolization and transarterial infusion chemotherapy using anthracycline in patients with hepatocellular carcinoma
Wahyu Purnama

10.20-10.30  
Lifestyle Habits and Nonalcoholic Fatty Liver Disease in the Multicenter CAP-Asia Study
Dr. Jimmy Lai for Zhang Xinrong

10.30-10.40  
A FIB-4-based risk score predicts hepatocellular carcinoma in patients with chronic hepatitis B
Terry Cheuk-Fung Yip for Lilian Yan Liang

10.40-10.50  
Risk of Spontaneous Bacterial Peritonitis with Use of Proton Pump Inhibitors Among Patients with Liver Cirrhosis “A Systematic Review and Meta-analysis”
Marianne Linley Sy

10.50-11.00  
Performance evaluation of a point-of-care (POC) molecular test (Xpert® HBV viral load (VL) assay) to strengthen and decentralize Hepatitis B virus management
Arvind Khodare

11.00-11.10  
Aspirin induces autophagy and alleviates liver fibrosis by modulating liver microbiome and reducing inflammation in mice model of chronic liver injury
Adil Bhat

11.10-11.20  
Care Cascade Achieved by a Program for Micro-elimination of Perinatal HBV Transmission among Pregnant Women in Peri-urban Yangon, Myanmar
Myat Sandi Min

11.20-11.30  
Hepatitis B Virus S Gene Mutation Analysis in Occult Hepatitis B Infection in Indigenous People of Keerom, Papua, Indonesia
Dhita Prabasari Wibowo

11.30-11.40  
Metagenomics Approach Identified Diversity and Composition of Tumor-infiltrating Microbiota in Hepatocellular Carcinoma
Yosuke Hirotsu

11.40-11.50  
Existence of hepatitis B surface protein mutations and other variants: Demand for hepatitis B infection control in Cambodia
Ko Ko

11.50-12.00  
Noninvasive indices for monitoring disease course as an Alternative to Vibration Controlled Transient Elastography in Liver Fibrosis Staging in Chronic Hepatitis C: Comparison of Data in Pre and Post-Treatment Period
Shubham Jain

12.00-13.00  
Lunch - Singaraja Hall
Treatment Efficacy and Safety of Sofosbuvir with Velpatasvir for chronic hepatitis C among uremic patients under maintenance hemodialysis—an interim report of ERASE-C
Ming-Lung Yu

Fatty liver is common, but did not predict adverse liver and non-liver outcomes in chronic hepatitis B patients
Sui-Weng Wong

Both hepatitis A and hepatitis D infection may be associated with more advanced liver disease in patients with chronic hepatitis B
Wu Jer-Wei

Lindsey Hiebert

Lindsey Hiebert

NS5B Drug Resistance Mutations in Naive Hepatitis C Virus-Infected Mexican Patients may Reduce Virological-Sustained Response to Direct-Acting Antivirals
Panduro Arturo

Genetic search started from resected samples of juvenile-onset human cholangiocarcinoma: SKI interacts with microRNA-3648 resulting in cell cycle regulation
Etsushi Kawamura

Longitudinal changes in controlled attenuation parameter and body mass index are associated with fibrosis evolution in chronic hepatitis B patients on nucleoside analogue therapy
Rex Wan-Hin Hui

Management Of Patients With Hepatitis B Virus Reactivation Post “DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV” HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis
Ali Abdelrahman Ghweil

Role of Serum Glypican-3 in the Diagnosis of Hepatocellular Carcinoma in the Upper Egypt
Ali Abdelrahman Ghweil

Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study
Ali Abdelrahman Ghweil

Development of a urine test for liver cancer screening
Ying-Hsiu Su
## ORAL Presentation

**Mengwi 5 Room - Session I**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-12.00</td>
<td>Chairman</td>
<td>Khin Maung Win, Myanmar Co-Chair Grace Wong, HongKong</td>
<td>Both alcoholic and non alcoholic steatohepatitis(BASH): A preliminary study from eastern India</td>
</tr>
<tr>
<td>10.00-12.00</td>
<td></td>
<td>Dinesh Meher</td>
<td>Impact of the liver volume change on share wave velocity (SWE)</td>
</tr>
<tr>
<td>10.20-10.30</td>
<td></td>
<td>Tsutomu Kanefuji</td>
<td>A STUDY ON THE ASSOCIATION BETWEEN SEVERITY OF FIBROSIS IN NON ALCOHOLIC FATTY LIVER DISEASE AND VISCERAL FAT VOLUME</td>
</tr>
<tr>
<td>10.30-10.40</td>
<td></td>
<td>Bony George</td>
<td>The Changes of Degree of Liver Fibrosis in Patients with Hepatitis B infection and Its Correlation to Duration of Therapy</td>
</tr>
<tr>
<td>10.40-10.50</td>
<td></td>
<td>Ni Wayan Wina Dharmesti</td>
<td>Analgesic efficacy of ultrasound - guided Erector spinae plane block for percutaneous biliary drainage - A randomized control trial</td>
</tr>
<tr>
<td>10.50-11.00</td>
<td></td>
<td>Nath Gautam</td>
<td>Relationship Of Post-Prandial Lipaemia And Inflammatory Markers In Cases Of Non-Alcoholic Fatty Liver Disease (NAFLD)</td>
</tr>
<tr>
<td>11.00-11.10</td>
<td></td>
<td>Moinak Sen Sarma</td>
<td>Pancreatic endosonographic changes in portal cavernoma cholangiopathy and effect of portosystemic shunt surgery in children</td>
</tr>
<tr>
<td>11.10-11.20</td>
<td></td>
<td>Patil N</td>
<td>Second Harmonic Generation (SHG) microscopy and Hepatic venous pressure gradient based validation of a novel histological staging system for alcoholic hepatitis</td>
</tr>
<tr>
<td>11.20-11.30</td>
<td></td>
<td>Sudrishti Chaudhary</td>
<td>Proteomic variations presented with chronic dose of alcohol can be captured in low and early exposure</td>
</tr>
<tr>
<td>11.30-11.40</td>
<td></td>
<td>Moinak Sen Sarma</td>
<td>Validation of Indian scoring system for diagnosis of Wilson disease in children</td>
</tr>
<tr>
<td>11.40-11.50</td>
<td></td>
<td>Wai-Kay Seto</td>
<td>Prevalence of concurrent non-alcoholic fatty liver disease in chronic hepatitis B patients using non-invasive multiparametric MRI</td>
</tr>
<tr>
<td>11.50-12.00</td>
<td></td>
<td>Mutiara Lirendra</td>
<td>Association Between Non-Alcoholic Fatty Liver Disease and Extrahepatic Malignancy Risk and Mortality: A Systematic Review</td>
</tr>
</tbody>
</table>

**Lunch - Singaraja Hall**
### ORAL Presentation

#### Friday

**Mengwi 2 Room - Session II**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13.00-15.00 | Chairman : Chan Wah Kheong, Malaysia  
Co-Chair : A.M Luthfi Parewangi, Indonesia                        |
| 13.00-13.10 | Anti-HBs level and its correlation with HBV infection profile in Indonesian population  
Korri Elvanita El-Khobar                                           |
| 13.10-13.20 | Changes in claudin 2 expression mediates increased gut permeability in patients with acute variceal bleed  
due to alcohol related cirrhosis  
Kanav Kaushal                                                    |
Verma Nipun                                                     |
| 13.30-13.40 | Hepatic Proteomic analysis reveals distinct molecular signatures in double hit model of thioacetamide and ethanol induced liver fibrosis in mice  
Sudrishti Chaudhary                                             |

#### Friday

**Mengwi 3 Room - Session II**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13.00-15.00 | Chairman : TC Tseng, Taiwan  
Co-Chair : Nasrul Zubir, Indonesia                        |
| 13.00-13.10 | Occult Hepatitis B infection in Hepatitis B-vaccinated elementary school children in Kupang, East Nusa Tenggara  
Muhammad Rezki Rasyak                                           |
| 13.10-13.20 | Quality Of Life, Psychosocial Burden And Mental Health Disorders In Primary Caregivers Of Patients With Cirrhosis  
Hareendran Atul                                                 |
| 13.20-13.30 | Serum cystatin C as a predictor of 90-day mortality in patients admitted with complications of cirrhosis  
Suksamai Anuchit                                                |
| 13.30-13.40 | HSD17B13 Insertion Variant Confers Protective Effect on Adverse Liver Outcomes in Patients with Non-alcoholic Fatty Liver Disease  
Ting Yi Wen                                                     |
| 13.40-13.50 | 5-aminolevulinic acid attenuates palmitate-induced endoplasmic reticulum stress and hepatocyte lipoapoptosis via heme oxygenase-1 induction.  
Takaaki Hashimoto                                               |
| 13.50-14.00 | The Role of Non-Neutral Mutation in the NSSA Region of HCV and Virological Response in HCV-HIV Coinfected Patients with Peg-IFN/RBV Therapy  
Juferdy Kurniawan                                               |
| 14.00-14.10 | Sarcopenia is a poor prognostic marker following curative resection for hepatocellular carcinoma “ a single centre experience  
Edward Gane                                                     |
| 14.10-14.20 | Progression pattern after lenvatinib therapy in patients with advanced hepatocellular carcinoma  
Sadahisa Ogasawara                                              |
13.00-15.00  
**Chairman**: Oidov Batarkhuu, Mongolia  
**Co-Chair**: Fauzy Yusuf, Indonesia

13.00-13.10  
**Glomerular Filtration Rate in Liver Cirrhosis**  
*Niza Amalya*

13.10-13.20  
**Expanding the Potential Benefits of Vitamin E in NAFLD Patients: A Meta-Analysis of Randomized Controlled Trials**  
*Adinda Ayu Dyah Rahadini*

13.20-13.30  
**Circulating platelets and plasma proteomic profiling during liver regeneration in living liver donors**  
*Adil Bhat*

13.30-13.40  
**Stem Cells Therapy as an Initial Treatment Prior to Liver Transplantation for Liver Cirrhosis Case**  
*Samuel Lionardi*

13.40-13.50  
**Non alcoholic fatty liver disease in Inflammatory bowel disease -tend to be lean ?**  
*Anju Krishna Krishnakumar*

13.50-14.00  
**Piloting practical innovations to increase the efficacy of traditional awareness modalities for general population for spreading awareness about hepatitis B and C infections**  
*Dr. Neeraj Raizada*

14.00-14.10  
**Curtailing the silent epidemic of Hepatitis B & C: Experiences in implementation of an innovative Call to action initiative**  
*Dr. Neeraj Raizada*

14.10-14.20  
**Study of the effect of the interleukin-18 gene rs1946518 polymorphism on the progression of chronic viral hepatitis B and chronic viral hepatitis C with a delta agent in the Kazakh population**  
*Ilyassova Bibigul*

14.30-14.40  
**TREATMENT NONALCOHOLIC STEATOHEPATITIS: OWN EXPERIENCE**  
*Ilyassova Bibigul*

14.40-14.50  
**RATIONAL PHARMACOTHERAPY OF PRIMARY BILIARY CHOLANGITIS. OWN EXPERIENCE**  
*Ilyassova Bibigul*

14.50-15.00  
**THE EFFECT OF HEPATOXYCELL STEM CELL IN VEGF AND CITOLOGY PATIENT OF HEPATOCELLULAR CARCINOMA (HEP G2)**  
*Asih Sasami Jati*
### Mengwi 2 Room - Session I

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-12.00</td>
<td>Chairman: Vincent Ho, Australia Co-Chair: Hery Dijagat Purnomo, Indonesia</td>
<td></td>
</tr>
<tr>
<td>10.00-10.10</td>
<td><strong>CORRELATION BETWEEN TNF-a SERUM AND DEGREE OF LIVER FIBROSIS BY FIBROSCAN IN CHRONIC LIVER DISEASE PATIENTS AT RSMH PALEMBANG</strong></td>
<td>Suyata</td>
</tr>
<tr>
<td>10.10-10.20</td>
<td><strong>ETHANOL EXTRACT of Garcinia mangostana L PERICARP INCREASE BLOOD ALBUMIN CONCENTRATION IN RAT LIVER FIBROSIS MODEL</strong></td>
<td>Triyanta Yuli Pramana</td>
</tr>
<tr>
<td>10.20-10.30</td>
<td><strong>Cost Analysis of Hospitalized Liver Cirrhosis Patients in Tertiary Referral Hospital</strong></td>
<td>Kemal F. Kalista</td>
</tr>
<tr>
<td>10.30-10.40</td>
<td>Are patients with non-alcoholic fatty liver disease (NAFLD) at risk of endothelial dysfunction?</td>
<td>Waleed Al-hamoudi</td>
</tr>
<tr>
<td>10.40-10.50</td>
<td><strong>Prevalence of Biopsy Proven Non Alcoholic Fatty Liver Among Patients with Gallstone disease</strong></td>
<td>Sara Alqahtani</td>
</tr>
<tr>
<td>10.50-11.00</td>
<td><strong>Baseline M2BP/Gi Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy</strong></td>
<td>Tai-Chung Tseng</td>
</tr>
<tr>
<td>11.00-11.10</td>
<td><strong>Burden of Chronic Liver Diseases (CLD) in Asia: The Growing Impact of Non-alcoholic Fatty Liver Diseases (NAFLD)</strong></td>
<td>Zobair M. Younossi</td>
</tr>
</tbody>
</table>

### Mengwi 3 Room - Session I

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-12.00</td>
<td>Chairman: Laurent Castera, France Co-Chair: Haris Widita, Indonesia</td>
<td></td>
</tr>
<tr>
<td>10.00-10.10</td>
<td><strong>Perioperative management for portal hypertension in patients with hepatocellular carcinoma</strong></td>
<td>Nobuyuki Takemura</td>
</tr>
<tr>
<td>10.10-10.20</td>
<td><strong>Feeding Phellodendron bark and its component berberine prevent nonalcoholic steatohepatitis-related fibrosis in mice</strong></td>
<td>Mayuko Ichimura-Shimizu</td>
</tr>
<tr>
<td>10.20-10.30</td>
<td><strong>Role of the Sabadell NIHCED (non-invasive hepatitis C related cirrhosis early detection) index and right lobe diameter to albumin ratio in prediction of presence of varices in patients with liver cirrhosis</strong></td>
<td>Amr Mohammed Zaghloul</td>
</tr>
<tr>
<td>10.30-10.40</td>
<td><strong>Same subtype but different strains of hepatitis A virus (HAV) causing outbreaks in two districts of one province in Indonesia almost at the same time</strong></td>
<td>Dewi Setyowati</td>
</tr>
<tr>
<td>10.40-10.50</td>
<td><strong>Decision curve analysis of non-invasive predictive tools for varices needing treatment in patients with chronic liver disease</strong></td>
<td>Samagra Agarwal</td>
</tr>
<tr>
<td>10.50-11.00</td>
<td><strong>Impact of transforming growth factor-beta1 gene polymorphism on the development of cirrhosis in chronic hepatitis C patients in Bangladesh</strong></td>
<td>Jahan Munira</td>
</tr>
<tr>
<td>11.00-11.10</td>
<td><strong>Study of Prevalence of Hepato-pulmonary Syndrome and its Correlation with CTP/MELD Scores</strong></td>
<td>Dinesh Meher</td>
</tr>
<tr>
<td>11.10-11.20</td>
<td><strong>NAFLD Disease Burden - Hong Kong, Singapore, South Korea, and Taiwan, 2020-2035</strong></td>
<td>Vincent WS Wong</td>
</tr>
</tbody>
</table>
ORAL Presentation

Saturday 07.03.2020

Mengwi 2 Room - Session II

13.00-15.00  Chairman : Poernomo Boedi Setiawan, Indonesia
Co-Chair : Fauzy Yusuf, Indonesia

13.00-13.10  Hepatocellular carcinoma post direct-acting antivirals in Australian hepatitis C-related advanced fibrosis/cirrhosis patients
Emilia Prakoso

13.10-13.20  Assessing the role of hepatology nurses in the management of patients with advanced liver disease in the outpatient setting.
Emilia Prakoso

13.20-13.30  A new role of cancer stem cell marker CD90/THY-1 in cell autophagy upon chemotherapy
Caecilia Sukowati

13.30-13.40  Distribution of cancer stem cells mRNA markers in HCC clinical samples: Eastern vs. Western populations
Caecilia Sukowati

13.40-13.50  Fibrosis Index Predicts Subsequent Esophageal variceal Bleeding in Patients with Compensated Cirrhosis and Initial Small Varices without Beta-Blocker or Band Ligation Prophylaxis.
Cheng-Fu Wang

13.50-14.00  THE SIDE EFFECTS OF DIRECT ACTING ANTIVIRALS IN HEPATITIS C PATIENTS ARE ASSOCIATED WITH OATP 334 T> G VARIANT
Zuhal MERT ALTINTAS

14.00-14.10  THE SIDE EFFECTS OF DIRECT ACTING ANTIVIRALS IN HEPATITIS C PATIENTS ARE ASSOCIATED WITH OATP 334 T> G VARIANT
Zuhal MERT ALTINTAS

14.10-14.20  Single doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in reduced plasma SSAO activity in healthy participants
Quirk Erin

Saturday 07.03.2020

Mengwi 3 Room - Session II

13.00-15.00  Chairman : Gontar A. Siregar, Indonesia
Co-Chair : Bogi Pratomo Wibowo, Indonesia

13.00-13.10  Early use of oral PEG3350 plus Lactulose vs. Lactulose alone enables early and sustained recovery of overt Hepatic Encephalopathy in patients with Acute on Chronic Liver Failure: An Open Label Randomized Controlled Trial
Madhumita Premkumar

13.10-13.20  Comparison of outcomes among decompensated and compensated cirrhosis with autoimmune hepatitis treated with steroids
Samagra Agarwal

13.20-13.30  Liver stiffness measurement by Fibroscan increases diagnostic accuracy in non-alcoholic fatty liver disease patients classified as indeterminate risk for advanced fibrosis according noninvasive scores
Yusuf Yilmaz

13.30-13.40  Effectiveness of hepatitis C treatment within National ãœRoadmap on prophylaxis, diagnostics, treatment and prevention of consequences of viral hepatitis in the Republic of Kazakhstan
Alexander Nersesov

Khanna Rajeev

13.50-14.00  A randomized placebo controlled trial of Tadalafil for erectile dysfunction in patients with cirrhosis
Rakesh Kumar Jagdish

14.00-14.10  Comparison of clinical and histological characteristics of biopsy-proven non-alcoholic fatty liver patients with and without type 2 diabetes mellitus: 10 years of experience from a single tertiary care center
Yusuf Yilmaz

14.10-14.20  Efficacy of liver stiffness measurement in the left lobe
Abe Satoshi

14.30-14.40  THE EFFECT OF HYPERBARIC OXYGEN THERAPY (HBOT) ON LIVER FUNCTION AND FIBROSIS USING A RAT MODEL OF CARBON TETRACHLORIDE (CCl4)-INDUCED LIVER INJURY: AN EXPERIMENTAL STUDY
Marc Julius H. Navarro

14.40-14.50  NASH Disease Burden - Hong Kong, Singapore, South Korea, and Taiwan, 2020-2035
Vincent WS Wong
## Workshop 1 - Nusa Dua Hall 1
### Session I Frontiers Endoscopy in Liver Disease
- **Chairman:** Kazuo Hara, Japan
- **Co-Chair:** Ari Fahrial Syam, Indonesia

### Intervention in Hepatobiliary
- **Course Director:** Shuichiro Shiina, Japan
  - Juferdy Kurniawan, Indonesia

### Endoscopic polypectomy in patients with advanced liver disease
- **Marcellus Simadibrata, Indonesia**

### ERCP in Advance Liver Cirrhosis
- **Begawan Bestari, Indonesia**

### ERCP and cholangioscopy in hepatobiliary diseases
- **Ari Fahrial Syam, Indonesia**

### Discussion
- **Juferdy Kurniawan, Indonesia**

- **Shuichiro Shiina, Japan**

- **RFA Basic Procedure Equipment and Preparation**
- **RFA in Liver Malignancies: Tips & Trick in Various Circumstances**

### RFA in Liver Malignancies: Tips & Trick in Various Circumstances
- **Diana A. Payawal, Philippines**

### RFA vs Microwave: Which is Better in liver Malignancies
- **Discussion**

## Workshop 2 - Nusa Dua Hall 2
### Session II EUS Innovation in Hepatobiliary Disorders
- **Chairman:** Kazuo Hara, Japan
- **Co-Chair:** M. Begawan Bestari, Indonesia

### Moving towards the diagnostic scene in Liver Biopsy: FNA vs. FNB
- **Lawrence Ho Khek Yu, Singapore (Webcam)**

### Intraductal Ultrasound in Biliary Malignancy
- **Murdani Abdullah, Indonesia**

### Impact of EUS in Gallbladder Drainage in Clinical Pratice
- **Mitsuhiro Kida, Japan**

### Current Status EUS-guided Biliary Drainage for Benign and Malignant Biliary Obstruction
- **Kazuo Hara, Japan**

### Discussion

## Welcome Speech & Opening Remarks
- **Kazuo Hara, Japan**

## Coffee Break

## Phantom Hands-on Workshop
- **All Faculties**

## Lunch - Singaraja Hall

## Welcome Dinner - Temple Garden Westin
## Scientific Schedule

### Wednesday 04.03.2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-18.30</td>
<td>Re-registration &amp; On site</td>
<td></td>
</tr>
<tr>
<td>08.00-12.10</td>
<td>Workshop 3 - Nusa Dua Hall 3</td>
<td>APASL-AASLD Clinical Research Workshop</td>
</tr>
<tr>
<td></td>
<td><strong>Workshop Director:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>W Ray Kim, USA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rino A. Gani, Indonesia</td>
<td></td>
</tr>
<tr>
<td>08.00-08.05</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rino A. Gani, Indonesia</td>
<td></td>
</tr>
<tr>
<td>08.05-08.30</td>
<td>Spectrum of Clinical Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>W. Ray Kim, USA</td>
<td></td>
</tr>
<tr>
<td>08.30-08.55</td>
<td>Setting Up Multicenter Studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jasmohan Bajaj, USA</td>
<td></td>
</tr>
<tr>
<td>08.55-09.35</td>
<td>Clinical trials: A to Z</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anna Lok, USA</td>
<td></td>
</tr>
<tr>
<td>09.35-10.00</td>
<td>Sample size and data analyses in RCTs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grace Wong, Hong Kong</td>
<td></td>
</tr>
<tr>
<td></td>
<td>08.00-10.00</td>
<td>Workshop 4 - Uluwatu Hall 1</td>
</tr>
<tr>
<td></td>
<td><strong>Chairman:</strong></td>
<td>Challenges in Liver Transplantation and Current Surgical Innovation in Hepatobiliary Disorders</td>
</tr>
<tr>
<td></td>
<td>Mureo Kasahara, Japan</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Co Chair:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wifanto S. Jeo, Indonesia</td>
<td></td>
</tr>
<tr>
<td>08.00-08.05</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rino A. Gani, Indonesia</td>
<td></td>
</tr>
<tr>
<td>08.05-08.30</td>
<td>Spectrum of Clinical Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>W. Ray Kim, USA</td>
<td></td>
</tr>
<tr>
<td>08.30-08.55</td>
<td>Setting Up Multicenter Studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jasmohan Bajaj, USA</td>
<td></td>
</tr>
<tr>
<td>08.55-09.35</td>
<td>Clinical trials: A to Z</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anna Lok, USA</td>
<td></td>
</tr>
<tr>
<td>09.35-10.00</td>
<td>Sample size and data analyses in RCTs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grace Wong, Hong Kong</td>
<td></td>
</tr>
<tr>
<td></td>
<td>09.15-09.40</td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>10.30-10.55</td>
<td>Getting Funding for Studies : Industry Sponsored and Investigator-Initiated Trials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rajender Reddy, USA</td>
<td></td>
</tr>
<tr>
<td>10.55-11.20</td>
<td>Preparing Your Abstract</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jasmohan Bajaj, USA</td>
<td></td>
</tr>
<tr>
<td>11.20-11.45</td>
<td>Giving an Effective Presentation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>W. Ray Kim, USA</td>
<td></td>
</tr>
<tr>
<td>11.45-12.10</td>
<td>Getting Your Manuscript Published</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guadalupe Garcia Tsao, USA</td>
<td></td>
</tr>
<tr>
<td>12.00-13.00</td>
<td></td>
<td><strong>Lunch - Singaraja Hall</strong></td>
</tr>
<tr>
<td>12.40-13.30</td>
<td>POSTER VIEWING</td>
<td></td>
</tr>
<tr>
<td></td>
<td>All Faculties</td>
<td></td>
</tr>
<tr>
<td>13.30-15.30</td>
<td>Oral Abstract Presentation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panelist</td>
<td></td>
</tr>
<tr>
<td>15.30-15.55</td>
<td>Panel Session: Life as an academic Hepatologist</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panelist</td>
<td></td>
</tr>
<tr>
<td>15.55-16.00</td>
<td>Closing/Awarding</td>
<td></td>
</tr>
<tr>
<td></td>
<td>W. Ray Kim, USA &amp; Kemal Fariz Kalista, Indonesia</td>
<td></td>
</tr>
<tr>
<td>18.30-20.00</td>
<td></td>
<td><strong>Welcome Dinner - Temple Garden Westin</strong></td>
</tr>
</tbody>
</table>

**Panelists:**
- Toar J.M. Lalisan, Indonesia
- Wifanto S. Jeo, Indonesia
- Adianto Nugroho, Indonesia
- Mureo Kasahara, Japan
Scientific Schedule

Wednesday 04.03.2020

Post Graduate Course - Nusa Dua Hall 4
Session I - All about Portal Hypertension

10.30-12.00
Chairman : Laurentius A. Lesmana, Indonesia
Co Chair : Saeed Hamid, Pakistan

10.30-10.50
Hepatic Fibrosis and Development of Portal Hypertension
Jordy Gracia-Sancho, Spain

10.50-11.10
Non Cirrhotic Portal Hypertension: Pathophysiology and Diagnostic Approach
Guadalupe Garcia Tsao, USA

10.55-11.10
Management of Non Cirrhotic Portal Hypertension and Portal Biliopathy
Saeed Hamid, Pakistan

11.10-11.30
Non Invasive Assessment of Subclinical and Clinical Portal Hypertension
Laurent Castera, France

11.30-11.50
Spontaneous Portal-Systemic Shunts, Diagnostic, Clinical, Relevance, and Management
Hitoshi Maruyama, Japan

12.00-13.00
Lunch - Singaraja Hall

Post Graduate Course - Nusa Dua Hall 4
Session II

13.00-15.00
Chairman : Laurent Castera, France
Co-Chair : C. Rinaldi A. Lesmana, Indonesia

13.00-13.20
Portal Hypertension in Children: Diagnosis and Management
Rajeev Khanna, India

13.20-13.40
Primary Prophylaxis Variceal Bleeding in Child C Cirrhosis
Zaigham Abbas, Pakistan

13.40-14.00
Acute Variceal Bleeding Management: Beyond Guideline
Guadalupe Garcia Tsao, USA

14.00-14.20
Approach to Prevent and Reverse Cirrhotic Cardiomyopathy
Vincent Ho, Australia

14.20-14.40
Advance Therapeutic Option in Portal Hypertension: Beyond Beta Blocker
Lianda Siregar, Indonesia

14.40-15.00
Finding the Bridge Between EUS and Liver Disease: Ready for Prime Time?
C. Rinaldi A. Lesmana, Indonesia

15.00-15.30
Coffee Break

Post Graduate Course - Nusa Dua Hall 4
Session III

15.30-16.30
Chairman : Guadalupe Garcia Tsao, USA
Co-Chair : Hitoshi Maruyama, Japan

15.30-15.50
Cutting-edge of Endoscopic Management in Nonalcoholic Fatty Liver Disease (NAFLD)
D. Nageshwar Reddy, India

15.50-16.10
Liver Transplantation in Portal Vein Thrombosis: Is Still Contraindication?
Masatoshi Makuuchi, Japan

16.10-16.30
Wrap up & Closing
C. Rinaldi A. Lesmana, Indonesia

18.30-20.00
Welcome Dinner - Temple Garden Westin
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairmen/Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00-16.00</td>
<td>Re-registration &amp; On site Including Morning Coffee Break (Jimbaran Lobby)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07.30-09.00</td>
<td>Symposium 1 - Nusa Dua Hall 1,2,3: Clinical Dilemma in Hepatitis B Virus Infection and Liver Transplantation</td>
<td></td>
<td>Chairman: W. Ray Kim, USA (email) Co-Chair: Poernomo Boedi Setiawan, Indonesia</td>
</tr>
<tr>
<td>07.30-09.00</td>
<td>Symposium 2 - Nusa Dua Hall 4: Autoimmune Liver Diseases: An Update</td>
<td></td>
<td>Chairman: F.X Pridady, Indonesia Co-Chair: Ignatia Sinta Murti, Indonesia</td>
</tr>
<tr>
<td>07.30-07.50</td>
<td>Treatment Strategy for HBeAg Positive Normal ALT Patients With Minimal or No Fibrosis</td>
<td></td>
<td>Poernomo Boedi Setiawan, Indonesia</td>
</tr>
<tr>
<td>07.50-08.10</td>
<td>Long Term Oral Antiviral Therapy Outcome in Decompensated Cirrhosis With or Without CKD</td>
<td></td>
<td>Anna Lok, USA</td>
</tr>
<tr>
<td>08.10-08.30</td>
<td>Precision Treatment of HBV Infection IDN Wibawa, Indonesia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30-08.50</td>
<td>Current Knowledge and Limitation Adianto Nugroho, Indonesia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.45-09.00</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>Presidential Lecture - Nusa Dua Hall 5</td>
<td></td>
<td>Chairman: Osamu Yokosuka, Japan Co-Chair: Lianda Siregar, Indonesia</td>
</tr>
<tr>
<td></td>
<td>New Insight of Bacterial Management in Liver Cirrhosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Laurentius A. Lesmana, Indonesia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30-12.15</td>
<td>Opening Ceremony Prof. Sarin’s Welcoming Speech (Video) &amp; Award Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Nusa Dua Hall 5)</td>
<td></td>
<td><strong>Lunch - Singaraja Hall</strong></td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>Industrial Symposium 1 - Nusa Dua Hall 1,2,3 (EISAI): A New Horizon in The Clinical Management of Unresectable Hepatocellular Carcinoma</td>
<td></td>
<td>Opening and Welcome Co-Chair: Lianda Siregar, Indonesia</td>
</tr>
<tr>
<td>13.00-13.05</td>
<td>Opening and Welcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.25-13.50</td>
<td>Medical Needs in Unresectable Hepatocellular Carcinoma - Lenvatinib Data Review</td>
<td></td>
<td>C. Rinaldi A. Lesmana, Indonesia</td>
</tr>
<tr>
<td>13.50-14.15</td>
<td>Role of Lenvatinib For Unresectable Hepatocellular Carcinoma: Case Sharing</td>
<td></td>
<td>Rino A. Gani, Indonesia</td>
</tr>
<tr>
<td>14.15-14.25</td>
<td>Discussion and Q n A</td>
<td></td>
<td>All Participant</td>
</tr>
<tr>
<td>14.25-14.30</td>
<td>Summary and Closing</td>
<td></td>
<td>Irsan Hasan, Indonesia</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>State of The Art Lecture 1 Nusa Dua Hall 1,2,3</td>
<td></td>
<td>Chairman: Irsan Hasan, Indonesia Co-Chair: M. Julwan Pribadi, Indonesia</td>
</tr>
<tr>
<td></td>
<td>Liver Transplantation for Small HCC: Where Do We Stand?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Toar J. M Lalisang, Indonesia</td>
<td></td>
<td><strong>State of The Art Lecture 2</strong></td>
</tr>
<tr>
<td></td>
<td>Nusa Dua Hall 4 (Video Conference)</td>
<td></td>
<td>Chairman: C. Rinaldi A. Lesmana, Indonesia</td>
</tr>
<tr>
<td></td>
<td>New Management Options for Severe Alcoholic Hepatitis</td>
<td></td>
<td>Shiv K. Sarin, India</td>
</tr>
</tbody>
</table>

05.03.2020 Thursday
### Scientific Schedule

**Thursday, 05.03.2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1: Special Interest Group 1 - Nusa Dua Hall 4</th>
<th>Session 2: Palliative Care in Hepato-Pancreato Biliary Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00-16.30</td>
<td><strong>Chairman:</strong> Hasmik Ghazinyan, Armenia</td>
<td><strong>Chairman:</strong> Sahat Matondang, Indonesia</td>
</tr>
<tr>
<td></td>
<td><strong>Co-Chair:</strong> Arles, Indonesia</td>
<td><strong>Co-Chair:</strong> Sri Inggriani, Indonesia</td>
</tr>
<tr>
<td>15.00-15.25</td>
<td>Palliative and Supportive Care for Patients</td>
<td>Microwave Ablation vs RFA</td>
</tr>
<tr>
<td></td>
<td>with End-Stage Liver Disease</td>
<td><strong>Shuichiro Shiba, Japan</strong></td>
</tr>
<tr>
<td>15.25-15.50</td>
<td>Palliative Endoscopic Management in Advanced</td>
<td>TACE in Large HCC: Option Beyond the Limit</td>
</tr>
<tr>
<td></td>
<td>Biliary Cancer</td>
<td><strong>Sahat B.R.E Matondang, Indonesia</strong></td>
</tr>
<tr>
<td></td>
<td><strong>D. Nageshwar Reddy, India</strong></td>
<td>How Can We Realize Anatomical Liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Resection for HCC</td>
</tr>
<tr>
<td>15.50-16.15</td>
<td>Pain Management in Advanced Liver Cancer</td>
<td><strong>Masatoshi Makuuchi, Japan</strong></td>
</tr>
<tr>
<td>16.15-16.30</td>
<td><strong>Dwi Pantja Wibowo, Indonesia</strong></td>
<td>RFA for Metastatic Liver Disease: Impact on</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient’s Outcome</td>
</tr>
<tr>
<td>16.30-16.50</td>
<td><strong>Discussion</strong></td>
<td><strong>Shi-Ming Lin, Taiwan</strong></td>
</tr>
</tbody>
</table>

**Coffee Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 3: Palliative and Supportive Care for Patients with End-Stage Liver Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30-15.50</td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>

### Session 4 - Nusa Dua Hall 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 4</th>
<th>Session 5 - Ultrasound Innovation and Cutting Edge in HCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.50-18.20</td>
<td><strong>Chairman:</strong> Norifumi Kawada, Japan</td>
<td><strong>Chairman:</strong> Hitoshi Maruyama, Japan</td>
</tr>
<tr>
<td></td>
<td><strong>Co-Chair:</strong> F. Soemanto Padmomartono, Indonesia</td>
<td><strong>Co-Chair:</strong> Imelda M. Loho, Indonesia</td>
</tr>
<tr>
<td>16.50-17.10</td>
<td>Diagnostic approach and stratification management of coagulation disorders in liver cirrhosis</td>
<td>How to Evaluate Chronic Liver Disease Based on Ultrasound Diagnosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Andri Sanitoyo Sulaiman, Indonesia</strong></td>
</tr>
<tr>
<td>17.10-17.30</td>
<td>Safety issue on long-term oral anti-platelet or anticoagulant therapy in liver cirrhosis patients</td>
<td>The Role of CEUS for Liver Cancer Screening and Evaluation</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Hitoshi Maruyama, Japan</strong></td>
</tr>
<tr>
<td>17.30-17.50</td>
<td>Splenectomy in Liver Cirrhosis Patients With Hypersplenism and Splenomegaly</td>
<td>The Role of RFA in Intermediate Stage of HCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Shi-Ming Lin, Taiwan</strong></td>
</tr>
<tr>
<td>17.50-18.10</td>
<td>Our 30 years Experience of Living Donor Liver Transplantation</td>
<td>Innovation of Fusion Ultrasound in Managing Liver Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Rino A. Gani, Indonesia</strong></td>
</tr>
<tr>
<td>18.10-18.20</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Sponsored Dinner Symposium by Minophagen - Dexa Medica

**New Strategies for Management of Chronic Hepatitis**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 6</th>
<th>Session 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.30-20.00</td>
<td><strong>Chairman:</strong> Irsan Hasan, Indonesia</td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>

18.30-18.50 Management of Acute on Chronic Liver Failure an Algorithmic Approach

18.50-19.10 Reversibility of Hepatic Fibrosis in Chronic Hepatitis

19.10-19.30 **Jia-Horng Kao, Taiwan**

19.30-20.00 **Dinner**

---

**Symposium 3 - Nusa Dua Hall 4**

**Symposium 5 - Nusa Dua Hall 5**

**SPONSORED DINNER SYMPOSIUM (Minophagen-Dexa Medica) - Nusa Dua Hall 1,2,3**
## Scientific Schedule

### Friday 06.03.2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 08.00-17.00| Symposium 6 - Nusa Dua Hall 1,2,3  
Pediatric Hepatology                              |
| 08.00-09.30| Chairman : Hanifah Oswari, Indonesia  
Co-Chair : Fatima Safira Alatas, Indonesia         |
| 08.00-08.20| Abnormal Liver Enzyme Levels in an Adolescent: What Should You Do?  
Ninung Rose, Indonesia                            |
| 08.20-08.40| Pediatric NAFLD : How to Approach?  
Fatima Safira Alatas, Indonesia                    |
| 08.40-09.00| Referring Patients for Liver Transplantation : Indication, Timing, and The Preparation to Transplantation  
Hanifah Oswari, Indonesia                          |
| 09.00-09.20| Discussion                                                                             |
|           | Symposium 7 - Nusa Dua Hall 4  
Perspective on NAFLD in Asia                      |
| 08.00-09.30| Chairman : Khin Maung Win, Myanmar  
Co-Chair : Vnent Wong, HongKong                   |
| 08.00-08.20| NAFLD in Asian countries: From Risk Factors, Pathogenesis to Clinical Manifestations  
Vnent Wong, HongKong                               |
| 08.20-08.40| Pathological Point of View in NAFLD with Hepatitis Virus Infection  
Marini Stephanie, Indonesia                        |
| 08.40-09.00| Management Strategy for NAFLD/NASH: Asian’s Perspective  
Hery Djabat Purnomo, Indonesia                    |
| 09.00-09.20| Bariatric Surgery in NAFLD: Safety and Efficacy  
Errawan Wiradisuria, Indonesia                     |
| 09.20-09.30| Discussion                                                                             |
|           | Symposium 8 - Nusa Dua Hall 5  
Perspective on NAFLD in Asia                      |
| 08.00-09.30| Chairman : Oidov Batarkhuu, Mongolia  
Co-Chair : Agustinus Taolin, Indonesia            |
| 08.00-08.20| HBV - HCV co infection: Viral Load and Outcome after HCV Therapy  
Ming Lung Yu, Taiwan                              |
| 08.20-08.40| Treatment Strategy in Special Population (CKD, HIV, Pregnancy)  
CJ Liu, Taiwan                                    |
| 08.40-09.00| The Role of Gut-dysbiosis in Chronic Hepatitis C Virus Infection  
Yasuhiito Tanaka, Japan                           |
| 09.00-09.20| Global Burden of HCV Infection in Eastern Country and its Impact on Treatment Policy  
David H. Muljono, Indonesia                       |
| 09.20-09.30| Discussion                                                                             |
| 09.30-10.00| Coffee Break                                                                           |
## Scientific Schedule

### Friday 06.03.2020

#### Special Interest Group 2 - Nusa Dua Hall 1,2,3
- **Liver Fibrosis**
  - **Chairman:** Laurent Castera, France
  - **Co-Chair:** IDN Wibawa, Indonesia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10.00-11.30| **Algorithmic Approach for Diagnostic of F2 and F3 Fibrosis Using Non-Invasive Test**
            | **Laurent Castera, France**                                             |
| 10.00-10.25| **Innovation Imaging to Assess Liver Fibrosis:**
            | **Focus on MR-Elastography**                                           |
            | **Sri Inggriani, Indonesia (Video conference)**                        |
| 10.00-11.30| **Treatment in Liver Fibrosis:**
            | **How Far We Have Achieved and Its Outcome**                           |
            | **Kemal Fariz Kalista, Indonesia**                                     |
| 10.00-11.30| **Discussion**                                                          |

#### Symposium 9 - Nusa Dua Hall 4
- **New Issues on Hepatocellular Carcinoma**
  - **Chairman:** Han-Chieh Lin, Taiwan
  - **Co-Chair:** Bogi Pratomo Wibowo, Indonesia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10.00-11.30| **Liver Stiffness Measured by Fibroscan is Associated with Microvascular Complications in Filipinos with Diabetes Mellitus**
            | **Leila Sawadjaan**                                                     |
| 10.00-11.30| **Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer**
            | **- Video Conference**                                                  |
            | **Stephanie Seah**                                                      |
| 10.00-11.30| **MIP1β, sEselectin, Fractalkine and HLADR as early prognostic markers to discriminate Systemic Inflammatory Responses Syndrome (SIRS) from Acute on Chronic Liver Failure patients in 6 hours of admission: A single centre prospective study**
            | **- Video Conference**                                                  |
            | **Nirupama Trehanpati**                                                 |
| 10.00-11.30| **Pegbelfermin (PGBF) reduces serum levels of secondary bile acids (BAs) in patients with non-alcoholic steatohepatitis (NASH)**
            | **- Video Conference**                                                  |
            | **Edgar D. Charles**                                                    |
| 10.00-11.30| **The toll-like receptor 8 (TLR8) agonist selgantolimod induces a dose-dependent immune response in chronic hepatitis B patients**
            | **- Video Conference**                                                  |
            | **Jeffrey Wallin**                                                      |

#### Symposium 10 - Session 1 - Presidential Plenary (Best Abstract) - Nusa Dua Hall 5
- **New Paradigm on Hepatocellular Carcinoma in NAFLD**
  - **Irsan Hasan, Indonesia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10.00-11.15| **Liver Stiffness Measured by Fibroscan is Associated with Microvascular Complications in Filipinos with Diabetes Mellitus**
            | **Leila Sawadjaan**                                                     |
| 10.00-11.15| **Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer**
            | **- Video Conference**                                                  |
            | **Stephanie Seah**                                                      |
| 10.00-11.15| **MIP1β, sEselectin, Fractalkine and HLADR as early prognostic markers to discriminate Systemic Inflammatory Responses Syndrome (SIRS) from Acute on Chronic Liver Failure patients in 6 hours of admission: A single centre prospective study**
            | **- Video Conference**                                                  |
            | **Nirupama Trehanpati**                                                 |
| 10.00-11.15| **Pegbelfermin (PGBF) reduces serum levels of secondary bile acids (BAs) in patients with non-alcoholic steatohepatitis (NASH)**
            | **- Video Conference**                                                  |
            | **Edgar D. Charles**                                                    |
| 10.00-11.15| **The toll-like receptor 8 (TLR8) agonist selgantolimod induces a dose-dependent immune response in chronic hepatitis B patients**
            | **- Video Conference**                                                  |
            | **Jeffrey Wallin**                                                      |

#### State of The Art Lecture 3 - Nusa Dua Hall 1,2,3
- **Controversies and New Perspectives in Occult Hepatitis B Infection**
  - **Anna Lok, USA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11.30-12.00| **State of The Art Lecture 3 - Nusa Dua Hall 1,2,3**
            | **Chairman: Laurentius A. Lesmana, Indonesia**                          |
            | **Co-Chair : Triyanta Yuli Pramana, Indonesia**                         |
            | **Controversies and New Perspectives in Occult Hepatitis B Infection**  |
            | **Anna Lok, USA**                                                      |

#### Friday Prayer - Kintamani Hall 1 & Lunch - Singaraja Hall
- **12.00-13.30**
### Scientific Schedule

**Friday 06.03.2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30-15.00</td>
<td><strong>Symposium 11 - Nusa Dua Hall 1,2,3</strong>&lt;br&gt;General Hepatology Update Symposium</td>
</tr>
<tr>
<td>13.30-13.55</td>
<td>Chairman : Edward Gane, New Zealand&lt;br&gt;Co-Chair : Igor Vladimirovich Malov, Russia</td>
</tr>
<tr>
<td>13.55-14.20</td>
<td>Acute Hepatitis A Infection: Outbreak and Impact on Vaccination&lt;br&gt;<strong>Irsan Hasan, Indonesia</strong></td>
</tr>
<tr>
<td>14.20-14.45</td>
<td>Acute Hepatitis C Infection: Management in the era of DAA&lt;br&gt;<strong>Chen-Hua Liu, Taiwan</strong></td>
</tr>
<tr>
<td>14.45-15.00</td>
<td>Discussion</td>
</tr>
<tr>
<td>13.30-13.50</td>
<td><strong>Symposium 12 - Nusa Dua Hall 4</strong>&lt;br&gt;Update on Biliary Diseases</td>
</tr>
<tr>
<td>13.30-13.50</td>
<td>Chairman : Zaigham Abbas, Pakistan&lt;br&gt;Co-Chair : Ruswhandi, Indonesia</td>
</tr>
<tr>
<td>13.50-14.10</td>
<td>The Challenging Diagnosis of Cholangiocarcinoma&lt;br&gt;<strong>Sahat B.R.E Matondang, Indonesia</strong></td>
</tr>
<tr>
<td>14.10-14.30</td>
<td>Controversial Issue on Endoscopic Management in Malignant Biliary Obstruction&lt;br&gt;<strong>Kazuo Hara, Japan</strong></td>
</tr>
<tr>
<td>14.30-14.50</td>
<td>Molecular Pathology of Biliary Tract Cancer&lt;br&gt;<strong>Ening Krisnuhoni, Indonesia</strong></td>
</tr>
<tr>
<td>14.50-15.00</td>
<td>Surgical Management in Hepato-Cholangiocarcinoma&lt;br&gt;<strong>Wifanto S. Jeo, Indonesia</strong></td>
</tr>
<tr>
<td>15.00-18.00</td>
<td><strong>APASL 2020 - Web Symposium (China) - Nusa Dua Hall 5</strong></td>
</tr>
<tr>
<td>15.00-15.05</td>
<td>Introduction&lt;br&gt;<strong>Lai Wei, China</strong>&lt;br&gt;<strong>JiDong Jia, China</strong></td>
</tr>
<tr>
<td>15.05-15.25</td>
<td>PBC: Management of UDCA Refractory PBS&lt;br&gt;<strong>JiDong Jia, China</strong></td>
</tr>
<tr>
<td>15.25-15.45</td>
<td>Prevention of HBV-related HCC&lt;br&gt;<strong>George K.K Lau, HongKong</strong></td>
</tr>
<tr>
<td>15.45-16.05</td>
<td>NAFLD in Asian countries: From Risk factors, pathogenesis to clinical&lt;br&gt;<strong>Jian Gao Fan, China</strong></td>
</tr>
<tr>
<td>16.05-16.25</td>
<td>Dynamics of immune dysregulation as a guide for prevention and intervention for sepsis&lt;br&gt;<strong>Qin Ning, China</strong></td>
</tr>
<tr>
<td>16.25-16.45</td>
<td>Treatment in liver fibrosis: how far we have achieved and its outcome&lt;br&gt;<strong>Hong You, China</strong></td>
</tr>
<tr>
<td>16.45-17.05</td>
<td>DAAs treatment in Chinese population: its impact after SVR&lt;br&gt;<strong>Guofeng Chen, China</strong></td>
</tr>
<tr>
<td>17.05-17.25</td>
<td>Unmet needs in diagnosis and monitoring of portal hypertension&lt;br&gt;<strong>Xiaolong Qi, China</strong></td>
</tr>
<tr>
<td>17.25-17.45</td>
<td>Liver transplantation in Alcoholic Liver Diseases&lt;br&gt;<strong>James Fung/Wai-Kay Seto, HongKong</strong></td>
</tr>
<tr>
<td>17.45-17.55</td>
<td>Discussion&lt;br&gt;<strong>All Faculty</strong></td>
</tr>
<tr>
<td>17.55-18.00</td>
<td>Closing&lt;br&gt;<strong>Ji Dong Jia, China</strong></td>
</tr>
</tbody>
</table>

**Faculty Dinner - Karang Asem 1 Ballroom, Grand Hyatt Hotel**

18.00-20.00
**Symposium 13 - Nusa Dua Hall 1,2,3**  
**Presidential Plenary (Best Abstract)**

08.00-09.30  
**Chairman:** Ulrich H. Beuers, The Netherlands  
**Co-Chair:** David H. Muljono, Indonesia

- **Efficacy and Safety of Oral TLR8 Agonist Selgantolimod (GS-9688) In Virally-Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2, Randomized, Double-Blind Placebo-Controlled, Multi-Center Study**  
  *Edward Gane, New Zealand*

- **Hepatitis B virus (HBV) surface antigen (HBsAg) reduction with ISIS 505358 in treatment-naive chronic hepatitis B (CHB) patients: a phase 2a, randomized, double-blind, placebo-controlled study**  
  *Dr. Dickens Theodore*

- **CHI3L1 as a non-invasive marker for effective selecting of chronic HBV patient with normal ALT levels but with advanced liver fibrosis for treatment**  
  *Grace L.H Wong, Hong Kong*

- **Preliminary results of Phase II study: 100% SVR rates following twelve-week treatment with narlaprevir ritonavir and sofosbuvir combination in patients with HCV Genotype 1 infection**  
  *Vasily A. Isakov*

- **Transcriptional response to RO7020531, a novel double prodrug of a toll-like receptor 7 agonist, in whole blood of healthy subjects and chronic hepatitis B patients - Video conference**  
  *Tomas Racek*

**Symposium 15- Nusa Dua Hall 5**  
**Update on HCC**

08.00-09.30  
**Chairman:** TC Tseng, Taiwan  
**Co-Chair:** Irsan Hasan, Indonesia

- **Hepatitis Virus Infection and Its Impact on DILI**  
  *Chyntia O.M Jasirwan, Indonesia*

- **Respiratory Failure in Liver Cirrhosis**  
  *Martin Rumende, Indonesia*

- **Precaution and Assessment for DILI Prevention from Tuberculosis Drugs**  
  *Andri Sanityoso, Sulaiman, Indonesia*

- **Fungal Infection Management in Liver Cirrhosis**  
  *Rino A. Gani, Indonesia*

08.00-17.00  
**Re-registration & On site**

**Saturday 07.03.2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-17.00</td>
<td>Re-registration &amp; On site</td>
</tr>
<tr>
<td>08.00-09.30</td>
<td>Symposium 13 - Nusa Dua Hall 1,2,3</td>
</tr>
<tr>
<td>08.00-09.30</td>
<td><strong>Chairman:</strong> Ulrich H. Beuers, The Netherlands</td>
</tr>
<tr>
<td>08.00-09.30</td>
<td><strong>Co-Chair:</strong> David H. Muljono, Indonesia</td>
</tr>
</tbody>
</table>
| 08.00-08.15 | Efficacy and Safety of Oral TLR8 Agonist Selgantolimod (GS-9688) In Virally-Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2, Randomized, Double-Blind Placebo-Controlled, Multi-Center Study  
*Edward Gane, New Zealand* |
| 08.15-08.30 | Hepatitis B virus (HBV) surface antigen (HBsAg) reduction with ISIS 505358 in treatment-naive chronic hepatitis B (CHB) patients: a phase 2a, randomized, double-blind, placebo-controlled study  
*Dr. Dickens Theodore* |
| 08.30-08.45 | CHI3L1 as a non-invasive marker for effective selecting of chronic HBV patient with normal ALT levels but with advanced liver fibrosis for treatment  
*Grace L.H Wong, Hong Kong* |
| 08.45-09.00 | Preliminary results of Phase II study: 100% SVR rates following twelve-week treatment with narlaprevir ritonavir and sofosbuvir combination in patients with HCV Genotype 1 infection  
*Vasily A. Isakov* |
| 09.00-09.15 | Transcriptional response to RO7020531, a novel double prodrug of a toll-like receptor 7 agonist, in whole blood of healthy subjects and chronic hepatitis B patients - Video conference  
*Tomas Racek* |
| 08.00-09.30 | Symposium 14- Nusa Dua Hall 4                                         |
| 08.00-09.30 | **Chairman:** Oidov Batarkhuu, Mongolia                                |
| 08.00-09.30 | **Co-Chair:** Putut Bayupurnama, Indonesia                             |
| 08.00-08.20 | Hepatitis Virus Infection and Its Impact on DILI  
*Chyntia O.M Jasirwan, Indonesia* |
| 08.20-08.40 | Respiratory Failure in Liver Cirrhosis  
*Martin Rumende, Indonesia* |
| 08.40-09.00 | Precaution and Assessment for DILI Prevention from Tuberculosis Drugs  
*Andri Sanityoso, Sulaiman, Indonesia* |
| 09.00-09.20 | Fungal Infection Management in Liver Cirrhosis  
*Rino A. Gani, Indonesia* |
| 09.20-09.30 | Discussion                                                             |
| 09.30-10.00 | **Coffee Break**                                                      |
| 08.00-09.30 | Symposium 15- Nusa Dua Hall 5                                         |
| 08.00-09.30 | **Chairman:** TC Tseng, Taiwan                                        |
| 08.00-09.30 | **Co-Chair:** Irsan Hasan, Indonesia                                  |
| 08.00-08.25 | Hbc Antigen and The Risk of HCC                                       |
| 08.25-08.50 | Variant HCCs, Diagnosis and Clinical Consequences  
*TC Tseng, Taiwan* |
| 08.50-09.15 | Stratification for Prediction in Patient’s Outcome After Loco-Regional Therapy  
*Ening Krishnouhoni, Indonesia* |
| 09.15-09.30 | Discussion                                                             |

**Symposium 14- Nusa Dua Hall 4**  
**Critical Care in Hepatology**

**Symposium 15- Nusa Dua Hall 5**  
**Update on HCC**
### Symposium 16 - Nusa Dua Hall 1,2,3
**Liver Cirrhosis: New Issue on Management**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-11.30</td>
<td>Chairman: Rajender Reddy, USA  Co-Chair: Fauzi Yusuf, Indonesia</td>
<td></td>
</tr>
<tr>
<td>10.00-10.25</td>
<td>Sarcopenia in Liver Cirrhosis: Update in Pathogenesis and Management</td>
<td>Rajender Reddy, USA</td>
</tr>
<tr>
<td>10.25-10.50</td>
<td>MHE: Treat or Not</td>
<td>Imelda M. Loho, Indonesia</td>
</tr>
<tr>
<td>10.50-11.15</td>
<td>Gut-Microbiota in Liver Cirrhosis: All or None</td>
<td>Jasmohan Bajaj, USA</td>
</tr>
<tr>
<td>11.15-11.30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Symposium 18 - Nusa Dua Hall 5
**Stem Cell in Liver Diseases**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-11.30</td>
<td>Chairman: Ian Homer Y. Cua, Philippines  Co-Chair: Paulus Kusnanto, Indonesia</td>
<td></td>
</tr>
<tr>
<td>10.00-10.25</td>
<td>Hepatobiliary Stem Cells: Facts and Fancies</td>
<td>Chyntia O.M Jasirwan, Indonesia</td>
</tr>
<tr>
<td>10.25-10.50</td>
<td>Current Perspective Regarding Stem Cells Based Therapy for non-viral Liver Disease</td>
<td>Jeanne Adiwintana Pawitan, Indonesia</td>
</tr>
<tr>
<td>10.50-11.15</td>
<td>Safety Issue in Stem Cell Therapy</td>
<td>Cosphiadi Irawaan, Indonesia</td>
</tr>
<tr>
<td>11.15-11.30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Symposium 17 - Nusa Dua Hall 4
**Women in Hepatology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-11.30</td>
<td>Chairman: Rosmawati Mohammed, Malaysia  Co-Chair: Fardah Akil, Indonesia</td>
<td></td>
</tr>
<tr>
<td>10.00-10.25</td>
<td>Woman and Alcoholic Liver Disease</td>
<td>Fardah Akil, Indonesia</td>
</tr>
<tr>
<td>10.25-10.50</td>
<td>Fatty Liver in Pregnancy: Approach and Management</td>
<td>Grace Wong, Hongkong</td>
</tr>
<tr>
<td>10.50-11.15</td>
<td>Management of Chronic Hepatitis B in Pregnancy</td>
<td>Rosmawati Mohamed, Malaysia</td>
</tr>
<tr>
<td>11.15-11.30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Symposium 19 - Nusa Dua Hall 6
**AsiAP17 - Nusa Dua Hall 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-11.30</td>
<td>Chairman: Khin Maung Win, Myanmar  Co-Chair: Rino A. Gani, Indonesia</td>
<td></td>
</tr>
<tr>
<td>10.00-10.25</td>
<td>Immunotolerant Phase in Chronic Hepatitis B: Should We Treat?</td>
<td>C. Rinaldi A. Lesmana, Indonesia</td>
</tr>
<tr>
<td>10.25-10.50</td>
<td>Current Barriers to Hepatitis B Management-Asia Perspective</td>
<td>Rosmawati Mohamed, Malaysia</td>
</tr>
<tr>
<td>10.50-11.15</td>
<td>Tenofovir Alafenamide in The Management of CHB: Time to Switch?</td>
<td>Rino A. Gani, Indonesia</td>
</tr>
<tr>
<td>11.15-12.30</td>
<td>Asian Consensus Recommendations on Optimizing the Diagnosis and Initiation of Treatment of Hepatitis B Virus Infection in Resource-Limited Settings</td>
<td>Edward Gane, Australia</td>
</tr>
</tbody>
</table>

### Lunch - Singaraja Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.30-14.00</td>
<td>Chairman: Khin Maung Win, Myanmar  Co-Chair: Rino A. Gani, Indonesia</td>
<td></td>
</tr>
<tr>
<td>12.30-12.50</td>
<td>Immunotolerant Phase in Chronic Hepatitis B: Should We Treat?</td>
<td>C. Rinaldi A. Lesmana, Indonesia</td>
</tr>
<tr>
<td>12.50-13.10</td>
<td>Current Barriers to Hepatitis B Management-Asia Perspective</td>
<td>Rosmawati Mohamed, Malaysia</td>
</tr>
<tr>
<td>13.30-13.50</td>
<td>Asian Consensus Recommendations on Optimizing the Diagnosis and Initiation of Treatment of Hepatitis B Virus Infection in Resource-Limited Settings</td>
<td>Edward Gane, Australia</td>
</tr>
<tr>
<td>13.50-14.00</td>
<td>Panel Discussion: Strategies to Increase Treatment Rate for Chronic Hepatitis B in South-East Asia</td>
<td></td>
</tr>
</tbody>
</table>
## Scientific Schedule

### Saturday 07.03.2020

#### Symposium 19 - Nusa Dua Hall 1,2,3
NAFLD and Other Related Problem

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-15.30</td>
<td>Chairman: Iswan A. Nusi, Indonesia, Co-Chair: C. Rinaldi A. Lesmana, Indonesia</td>
<td>14.00-15.30</td>
<td></td>
</tr>
<tr>
<td>14.00-14.20</td>
<td>Update Pathophysiology Concept Related to Other Metabolic Parameters</td>
<td>14.00-14.25</td>
<td>Hery Djagat Purnomo, Indonesia</td>
</tr>
<tr>
<td></td>
<td>Hery Djagat Purnomo, Indonesia</td>
<td>14.25-14.50</td>
<td></td>
</tr>
<tr>
<td>14.40-15.00</td>
<td>NAFLD and Coronary Arterial Disease</td>
<td>15.15-15.30</td>
<td>Chan Wah Keong, Malaysia</td>
</tr>
<tr>
<td>15.00-15.20</td>
<td>NAFLD and Non Alcoholic Fatty Pancreas Diseases: Together in Line?</td>
<td></td>
<td>C. Rinaldi A. Lesmana, Indonesia</td>
</tr>
<tr>
<td>15.20-15.30</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Symposium 20 - Nusa Dua Hall 4
Infection in Hepatobiliary Diseases

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-15.30</td>
<td>Chairman: Ian Homer Y. Cua, Philippines, Co-Chair: F. X. Pridady, Indonesia</td>
<td>14.00-15.30</td>
<td></td>
</tr>
<tr>
<td>14.00-14.20</td>
<td>Tropical infection and Liver Toxicity</td>
<td></td>
<td>Saut Horas Nababan, Indonesia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14.25-14.50</td>
<td></td>
</tr>
<tr>
<td>14.20-14.40</td>
<td>Update Management in Pyogenic Liver Abscess</td>
<td></td>
<td>Jufery Kurniawan, Indonesia</td>
</tr>
<tr>
<td>14.40-15.00</td>
<td>Biliary Sepsis Management: Percutaneous, Endoscopic, or Surgical</td>
<td></td>
<td>Necati Ormeci, Turkey</td>
</tr>
<tr>
<td>15.00-15.20</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### APASL-EASL Joint Meeting - Uluwatu Hall 7
Managing Complication of Liver Disease

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-15.30</td>
<td>Chairman: Laurentius A. Lesmana, Indonesia, Co-Chair: Ulrich H. Beuers, The Netherlands</td>
<td>14.00-15.30</td>
<td></td>
</tr>
<tr>
<td>14.00-14.20</td>
<td>Diagnosis of Cirrhosis and Portal Hypertension: Non Invasive or Invasive Test?</td>
<td>Rino A. Gani, Indonesia</td>
<td></td>
</tr>
<tr>
<td>14.20-14.40</td>
<td>Bleeding and Thrombosis in End Stage Liver Disease</td>
<td>Cosphiadi Irawan, Indonesia</td>
<td></td>
</tr>
<tr>
<td>14.40-15.00</td>
<td>Management of Cholestatic Diseases and It’s Complications</td>
<td>Ulrich H. Beuers, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>15.00-15.20</td>
<td>Risk Model on HCC in CHB in the Past Decades: Is it practical?</td>
<td>George K.K. Lau, Hong Kong - Video Conference</td>
<td></td>
</tr>
<tr>
<td>15.20-15.30</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30-15.50</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>
Symposium 21 - Nusa Dua Hall 1,2,3  
Heart and Liver

15.50-17.20  
Chairman : Gontar A. Siregar, Indonesia  
Co-Chair : Riki Tenggara, Indonesia

15.50-16.15  
Cardiohepatic Disfunction: Interaction Pathogenesis and Clinical Manifestation  
Sally Aman Nasution, Indonesia

16.15-16.40  
Myocardial dysfunction Associated with Hepatitis B Virus Infection  
Ian Homer Y. Cua, Philippines

16.40-17.05  
Exercise for Liver Cirrosis Patients  
Irsan Hasan, Indonesia

17.05-17.20  
Discussion

Symposium 22- Nusa Dua Hall 4  
Lung and Liver

15.50-16.10  
Hepatopulmonary Syndrome: Update on Pathogenesis and Clinical Pictures  
Lianda Siregar, Indonesia

15.50-16.30  
Update on Medical Treatment for the Hepatopulmonary Syndrome  
Ignatia Sinta Murti, Indonesia

16.10-16.30  
The Impact of Liver Transplantation in the Patients with Hepatopulmonary Syndrome  
Vincent Ho, Australia

16.30-17.05  
Personalizing Care in Patients with Liver Cirrhosis  
Aghayeva Guñara, Azerbaijan

17.05-17.20  
Discussion

Symposium 23 - Uluwatu Hall 7  
Regression of Fibrosis and Portal Hypertension in CLD: Is It Really Feasible?

15.50-17.20  
Chairman : Norifumi Kawada, Japan  
Co-Chair : Jordi Gracia-Sancho, Spain

15.50-16.10  
Regression of Portal Hypertension - Mechanisms & New Therapeutics  
Jordi Gracia-Sancho, Spain

16.10-16.30  
Regression of Fibrosis - Current Evidence & Future Perspectives  
Norifumi Kawada, Japan

16.30-16.50  
Regression of Portal Hypertension & Fibrosis: Non-Viral Cirrhosis  
Saut Nababan, Indonesia

16.50-17.10  
Non-Invasive Assessment of Portal Hypertension & Fibrosis Regression  
Kemal Fariz Kalista, Indonesia

17.10-17.20  
Discussion

18.00-20.00  
GALA DINNER, AWARD PRESENTATION & CLOSING CEREMONY - Nusa Dua Hall 5
Organized By:

PT. PROHEPA
Gedung Menara Salemba (3rd Floor)
Jalan Salemba Raya. No. 5, Jakarta Pusat 10440

Phone: +62 21-3970-0188
Email: prohepa.id@gmail.com

Website: www.apasl2020.org | Email: info@apasl2020.org